Sugi Predict

Sugi Predict / Compounds / SCHEMBL2989104

SCHEMBL2989104

SCHEMBL2989104

CC(C)(C)[Si](C)(C)Oc1cccc(C(=O)O)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1C3 P42330 1/20 0.53
▸ KMT2A Q03164 1/20 0.50
▸ NR4A2 P43354 4/20 0.49
▸ NPC1 O15118 2/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ NR4A1 P22736 1/20 0.49
▸ NR4A3 Q92570 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ KMO O15229 1/20 0.45
▸ HSP90AA1 P07900 1/20 0.44
▸ HSP90AB1 P08238 1/20 0.44
▸ CA12 O43570 1/20 0.43
▸ CA1 P00915 1/20 0.43
▸ CA9 Q16790 1/20 0.43
▸ RXRA P19793 1/20 0.43
▸ RXRB P28702 1/20 0.43
▸ MITF O75030 1/20 0.42
▸ MRGPRX4 Q96LA9 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30785086 0.88 STS (0.50) AKR1C3KMT2AHSP90AA1HSP90AB1
SCHEMBL341880 0.87 KMT2A (0.53) KMT2ANPC1RAB9AHSP90AA1HSP90AB1
SCHEMBL2981524 0.86 HSP90AA1 (0.43) AKR1C3KMT2ANR4A2NPC1RAB9A
SCHEMBL25984931 0.86 PARP1 (0.58) HSP90AA1HSP90AB1CA12CA1CA9
SCHEMBL4346540 0.84 L3MBTL1 (0.50) KMT2ANPC1RAB9APOLBMRGPRX4
SCHEMBL21280074 0.84 HSP90AA1 (0.42) AKR1C3KMT2ANR4A2NPC1RAB9A
SCHEMBL2982620 0.84 ESR1 (0.42) AKR1C3KMT2ANPC1HSP90AA1HSP90AB1
SCHEMBL9986901 0.83 RAF1 (0.47) KMT2AHSP90AA1HSP90AB1CA12CA1
SCHEMBL555801 0.83 GSK3B (0.48) NR4A2NPC1RAB9ANR4A1NR4A3
SCHEMBL2676116 0.83 HSP90AA1 (0.41) KMT2ANPC1RAB9APOLBCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250186433-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF EPIVARIO, INC. 2025-06-12 — — US disclosed
US-12133852-B2 ACSS2 inhibitors and methods of use thereof EPIVARIO, INC. (US) 2024-11-05 — — US disclosed
CN-112159373-B Compound and application thereof in preparation of targeted PTL and/or NPC1L1 inhibition drugs 青岛大学 2023-10-20 — — CN disclosed
WO-2023104170-A1 COMPOUNDS FOR TREATING POLYQ-RELATED NEURODEGENERATIVE DISORDERS HANGZHOU JIJING PHARMACEUTICAL TECHNOLOGY LIMITED (CN) 2023-06-15 — — WO disclosed
WO-2023104170-A1 COMPOUNDS FOR TREATING POLYQ-RELATED NEURODEGENERATIVE DISORDERS HANGZHOU JIJING PHARMACEUTICAL TECHNOLOGY LIMITED (CN) 2023-06-15 — — WO disclosed
US-11465965-B2 Double-headed protease inhibitor UBE INDUSTRIES, LTD. (JP) 2022-10-11 — — US disclosed
US-20220305010-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD. (IL) 2022-09-29 — — US disclosed
CN-113149930-B Cell sugar transport channel inhibitor 天津大学 2022-09-02 — — CN disclosed
CN-114344307-A Treatment of cancer using oxoisoindole compounds 细胞基因公司 2022-04-15 — — CN disclosed
WO-2022063071-A1 COMPOUND AND USE THEREOF IN PREPARATION OF DRUG FOR TARGETED INHIBITION OF PTL AND/OR NPC1L1 青岛大学 2022-03-31 — — WO disclosed
WO-2006010637-A2 PYRIDINYLAMINES GPC BIOTECH AG (DE) 2006-02-02 — — WO disclosed
EP-1453822-A4 DEUTERIUM-BASED CHEMILUMINESCENT 1,2-DIOXETANES GIRI BRIJ P (US) 2004-11-24 — — EP disclosed
EP-1453822-A2 DEUTERIUM-BASED CHEMILUMINESCENT 1,2-DIOXETANES Giri, Brij P. (US) 2004-09-08 — — EP disclosed
WO-2003054506-A2 DEUTERIUM-BASED CHEMILUMINESCENT 1,2-DIOXETANES GIRI BRIJ PAL (US) 2003-07-03 — — WO disclosed
EP-0790991-A4 — — 1997-09-03 — — EP disclosed
EP-0790991-A1 NOVEL 1,2-DIOXETANE COMPOUNDS WITH HALOALKOXY GROUPS, METHODS OF PREPARATION AND USE TROPIX, INC. (US) 1997-08-27 — — EP disclosed
EP-0757052-A1 Di-substituted 1,2-dioxetane compounds having increased water solubility and assay compositions BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY (US) 1997-02-05 — — EP disclosed
EP-0757248-A2 Improved capsule chemistry analytical methods employing dioxetane chemiluminescence BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY (US) 1997-02-05 — — EP disclosed
WO-1996015122-A1 NOVEL 1,2-DIOXETANE COMPOUNDS WITH HALOALKOXY GROUPS, METHODS OF PREPARATION AND USE TROPIX, INC. (US) 1996-05-23 — — WO disclosed
WO-1994013629-A1 MANNITOL DERIVATIVES AND THEIR USE AS INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 1994-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250186433-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, GLS2, ADSS2 AKR1C3 551/4885KMT2A 1401/4885NR4A2 4500/4885
US-11465965-B2 Double-headed protease inhibitor TMPRSS15, SPINT2, PRSS2 AKR1C3 1019/4885KMT2A 1556/4885NR4A2 4570/4885
US-20220305010-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, GLS2, ADSS2 AKR1C3 551/4885KMT2A 1401/4885NR4A2 4500/4885
US-12133852-B2 ACSS2 inhibitors and methods of use thereof ACSS2, GLS2, ADSS2 AKR1C3 551/4885KMT2A 1401/4885NR4A2 4500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.